Introduction
============

In some critically ill patients, herpes simplex virus type 1 (HSV-1) is isolated from the upper or lower respiratory tract \[[@B1]-[@B15]\]. On the one hand, immunodepressed patients may be susceptible for transmission and acquisition of viral diseases, but on the other hand viral reactivation may occur and may contribute relatively little to morbidity and mortality. Indeed, reactivation of human herpes virus-6 is common in the critically ill and does not worsen outcome \[[@B16],[@B17]\]. In immunocompetent patients, however, isolation of HSV-1 may be associated with viral pneumonia, even if reactivation rather than primary infection is likely \[[@B6],[@B8],[@B18]\]. Although HSV-1 has been associated with acute respiratory distress syndrome (ARDS) or ventilator-associated pneumonia in the critically ill \[[@B1]-[@B14]\], either as primary or superimposed infection, there are only few reports that the virus has elicited an infectious host response, as demonstrated by a rise of serum antibodies, by bronchoscopic airway disease, by \"typical\" findings on computer tomography of the lungs, or by the presence of giant cells or nuclear inclusion bodies on cytology or biopsy of the lower respiratory tract \[[@B3],[@B5],[@B9],[@B10],[@B18]\]. Indeed, Tuxen et al. observed that prophylactic antiviral therapy in ARDS prevented HSV-1 emergence but did not affect ventilatory days and patient outcome \[[@B4]\]. The pathogenicity of the virus thus remains unknown, and the rare association between isolation of the virus in the critically ill and mortality may denote reactivation of the virus in immunodepressed patients with multiple organ failure and a poor outcome \[[@B1],[@B2],[@B11],[@B14],[@B15]\], rather than a symptomatic primary or superinfection contributing to death.

Assessing pulmonary capillary protein permeability noninvasively at the bedside, yielding the pulmonary leak index (PLI), could help to judge tissue injury, as previously described \[[@B18]-[@B20]\]. This radionuclide method involves ^67^Gallium (^67^Ga)-transferrin and ^99m^Technetium (^99m^Tc)-red blood cells. In bacterial pneumonia, for instance, the PLI is elevated and the increase above normal directly relates to the severity of the pneumonia, expressed as the lung injury score (LIS) \[[@B19]\]. In patients with acute lung injury (ALI) or ARDS in the course of bacterial pneumonia, the PLI is uniformly and greatly elevated above normal (up to 14.1 × 10^-3^/min) when LIS \> 2.5, and in 80% of patients with a LIS between 1.5 and 2.5 and mild injury \[[@B19]\]. Hence, the method yields a direct measure of permeability and an indirect measure of capillary injury in the lungs. The PLI is also elevated in interstitial lung disease \[[@B21]\].

In order to help differentiating between symptomatic and asymptomatic viral shedding and spread, which could help to decide on antiviral therapy, and thus in assessing the pathogenicity of the virus, we measured the PLI in 4 consecutive critically ill patients with persistent pulmonary infiltrates of unknown origin on ventilatory support, in whom a HSV-1 had been isolated.

Patients and methods
====================

We report on a small series of consecutive patients, in whom respiratory secretions, sent for viral cultures, because of persistent pulmonary infiltrates of unknown origin, proved positive for HSV-1 (Table [1](#T1){ref-type="table"}). Tracheal aspirates or bronchoalveolar lavage fluids were directly transported to the microbiology laboratory or placed into viral transport medium (Copan Diagnostics Inc. Corona CA, USA). For isolation of HSV-1, specimens were inoculated in standard fashion in triplicate flat bottom tubes on human embryonal lung fibroblasts and incubated at 37 EC. Cultures were read three times weekly for 10 days for cytopathic effect (CPE). If CPE indicating HSV-1 appeared or blindly at day 2 and day 7, cells were fixed in methanol/acetone (1:1) and typed by immunofluorescence with labelled specific HSV-1 and HSV-2 antibodies (Syva Mikrotac HSV-1/HSV-2 typing kit, Palo Alto, CA, USA). In the 4 patients reported, the results were available within 3 days after inoculation. On the day the specimen for viral culture was taken, demographic, chest radiographic and respiratory data were collected, as well as clinical features. In 3 of 4 patients on mechanical ventilation after intubation, the total respiratory compliance was calculated from ventilator settings, as tidal volume/(plateau -- end-expiratory pressure), in mL/cm H~2~O. From the radiographic score (ranging from 0 to 4 depending on the number of quadrants with radiographic opacities), the arterial PO~2~/inspiratory O~2~fraction (F~i~O~2~), the level of positive end-expiratory pressure and the compliance, the LIS \[[@B22]\], which ranges between 0 and 4, with values up to 2.5 denoting ALI and above 2.5 ARDS, was calculated. None of the patients had visible oropharyngeal vesicles.

Radionuclide method
-------------------

To further characterize the persistent pulmonary infiltrates, the PLI was measured with help of a modification of the method described before \[[@B19],[@B20]\]. Since this is a routine procedure, informed consent was waived. Autologous red blood cells were labeled with ^99m^Tc (11 MBq, physical half-live 6h; Mallincrodt Diagnostica, Petten, The Netherlands), using a modified in vitro method. Ten minutes after injection of the labeled red blood cells, transferrin was labeled in vivo, following i.v. injection of ^67^Ga-citrate (6 MBq, physical half-live 78 h; Mallincrodt Diagnostica, Petten, The Netherlands). Patients were in the supine position and two scintillation detection probes were positioned over the right and left lung apices. The probe system is manufactured by Eurorad C.T.T., Strasburg (Fr), and consists of two small cesium iodide scintillators (15 × 15 × 15 mm^3^) each in a 2 mm tungsten and 1 mm aluminum housing cover (35 mm diameter, 40 mm height). The front end of each probe has an aluminum flange attached (3 mm thick and 70 mm diameter), to facilitate easy fixation to the patient\'s chest with tape. Each probe weighs approximately 255 grams. The probe signals are led into a dual amplifier of which the output is fed into a multi-channel analyzer system connected to a personal computer. Since both probe have separate channels, there is no electronic cross-over. Starting at the time of the intravenous injection of ^67^Ga, radioactivity was detected every minute, during one hour. For each measurement interval, the entire spectrum of photon energies was stored on disk. During processing, the ^99m^Tc and ^67^Ga count rates were corrected for background radioactivity, physical half-live, spill-over of ^67^Ga into the ^99m^Tc window, obtained by in vitro measurement of ^67^Ga, and expressed as counts per minute (CPM) per lung field. At 5, 8, 11, 15, 20, 25, 30, 40, 50 and 60 minutes after ^67^Ga injection, blood samples (2 mL) were drawn, from the cannula in the radial or femoral artery. Each blood sample was weighed and radioactivity of 1 mL of blood was measured in duplicate for each blood sample. Radioactivity measurements of these samples were done with a single well well-counter (LKB Wallac 1480 WIZARD, Perkin Elmer, Life Science, Zaventem, Belgium). The software automatically corrects for background, spillover of ^67^Ga into ^99m^Tc and decay. Results were expressed as CPM/g. For each blood sample, a time-matched CPM over each lung was taken. A radioactivity ratio was calculated, (^67^Ga~lung~/ ^99m^Tc~lung~) / (^67^Ga~blood~/ ^99m^Tc~blood~), and plotted against time. The PLI was calculated, using linear regression analysis, from the slope of increase of the radioactivity ratio divided by the intercept, to correct for physical factors in radioactivity detection. By taking pulmonary blood volume and thus presumably surface area into account, the radioactivity ratio represents the ratio of extravascular versus intravascular ^67^Ga radioactivity. The PLI represents the transport rate of ^67^Ga-transferrin from the intravascular to the extravascular space of the lungs and is therefore a measure of pulmonary capillary permeability to transferrin \[[@B19],[@B20]\]. The mean of both lungs was taken. The upper limit of normal PLI is 14.1 × 10^-3^/min. Where appropriate, numbers are summarized as median (range).

Results
=======

The Table describes the patient data. The patients had stayed for some period in the hospital or intensive care unit before HSV-1 isolation and had been admitted primarily because of respiratory insufficiency, in the course of pneumonia. Patient 4 was admitted into the coronary care unit a few days prior to intensive care unit admission for cardiogenic pulmonary edema. All patients were dependent on mechanical ventilatory support, for some period prior to sampling. They had received adequate antibiotic therapy for pneumonia and had ALI at the time of sampling, of otherwise unknown origin. The Table shows that the patients had radiographic abnormalities without an increased PLI. Central venous pressure was not elevated, arguing against overhydration as a cause of persistent pulmonary infiltrates. In patients 1 and 3 a high resolution computer tomography scan of the lungs with contrast was obtained, but the findings were nonspecific with alveolar consolidations and pleural fluid, even in the presence of some interstitial abnomalities with some ground glass appearance in patient 3. In patient 1, a bronchoscopy was performed and there were no mucosal lesions. There was a normal distribution of lymphocyte subtypes in the lavage fluid. A transbrochial biopsy revealed interstitial inflammation with many macrophage depositions, and immunohistochemical staining for HSV-1 was negative. There were no multinucleated cells nor cell inclusions observed, both in bronchoalveolar lavage fluid of patient 1 or the tracheal aspirates of the other patients. In patients 1 to 3, concomitant isolation of bacteria by culture was regarded as bacterial colonisation. Antibody testing was not done in patients 2 to 4, and proved positive for IgG anti-HSV-1 in patient 1, indicative of a prior HSV-1 infection. Antiviral acyclovir was started when cultures became positive, at a dose of 10 mg/kg TID, in two patients, at the discretion of the treating physician. Acylcovir was withheld in the other two patients, in the presumption that the pulmonary infiltrates were not caused by HSV-1, on the basis of a normal PLI, among others. In patient 1 with a normal PLI, a course of steroids was started the day after the PLI, and continued in spite of positivity for HSV-1, reported 5 days later. All patients survived until discharge from the intensive care unit.

Discussion
==========

The ^67^Ga-transferrin PLI is a sensitive and specific measure of pulmonary capillary permeability, utilised for non-invasive severity assessment in a wide number of pulmonary conditions \[[@B19]-[@B21]\]. The PLI roughly parallels clinical severity, ie the LIS \[[@B19],[@B20]\]. Even though it involves relatively routine equipment, the diagnostic method has not gained wide application, partly because of its laborious nature \[[@B20]\]. It carries the advantage of bedside measurements in mechanically ventilated critically ill patients, who cannot be transported easily. Pulmonary inflammation, of whatever cause, increases the PLI up to fourfold normal values in most severe injury, including ARDS. In less severe injury, such as impending ARDS and interstitial lung disease, the PLI is also, albeit less, elevated, as reported by us and other groups \[[@B20],[@B21]\].

The patients had a prior infectious episode in common, followed by a relatively prolonged period of respiratory insufficiency. They had persistent and nonspecific pulmonary infiltrates of unknown origin, after treatment of their primary disease, prompting viral cultures. The normal PLI observed argues for a relatively harmless reactivation of the HSV-1, rather than a primary and damaging infection. In fact, critically ill patients with sepsis may have late immunodepression with lymphocytic apoptosis, lymphocytopenia, T-cell anergy, promoting viral reactivation \[[@B23],[@B24]\]. Apparently, the virus must have been latent in the nervous endings of the mucous membranes of the upper respiratory tract in these patients \[[@B2],[@B15]\]. Herpes viruses have been relatively frequently isolated in vivo from respiratory secretions of patients with ARDS \[[@B3],[@B4]\], and in surveillance cultures from the respiratory tract of patients after burns, trauma, transplantation, major surgery and others, but, fortuitously, in only 3% of lung biopsies of patients with prolonged and unresolving ARDS \[[@B3],[@B7],[@B9]-[@B13],[@B15]\]. The literature thus is widely divergent on the precise role of the virus in pulmonary disease in the critically ill and its contribution to patient morbidity and mortality \[[@B1]-[@B15]\].

We believe that the tracheal aspirates were representative of lower respiratory tract secretions, in the absence of herpes orolabialis and oral epithelial cells in smears for Gram stain of the secretions. The concurrent colonisation with other pathogens has been described before \[[@B5],[@B13]\]. Since there was no overlap in the duration of stay of the patients, transmission of the virus from one patient to the other can be excluded. This further suggests that respiratory HSV-1 infections in the critically ill may result from relatively harmless endogenous reactivation. Although the normal PLI argues against pulmonary parenchymal pathogenicity, tracheobronchitis caused by the virus \[[@B18],[@B25]\] cannot be ruled out, even in the absence of orolabial lesions, since bronchoscopy was not performed in 3 of the 4 patients, even though being unremarkable in patient 1. The persistent pulmonary infiltrates in our patients may thus relate to slow radiographic resolution of prior bacterial or aspiration pneumonia, rather then superimposed infection. Moreover, computer tomography lung images may be largely nonspecific \[[@B26]\], so that the precise diagnostic criteria for HSV-1 pneumonia remain unclear. When properly standardized, for instance relative to cell numberd in bronchoalveolar fluid or tracheal aspirates, quantitative cultures, viral RNA and DNA by polymerase chain reactions, could be helpful in further studies to quantitate viral load, the ratio of replication to shedding and thereby the pathogenicity of the virus in the lower respiratory tract.

In conclusion, our anecdotal data suggest that the isolation of HSV-1 from respiratory secretions in the critically ill patient with a persistent pulmonary infiltrate may warrant evaluation of tissue injury by the virus to judge its pathogenicity, for instance with help of a radionuclide PLI measurement, to help guide decisions on antiviral therapy, which may have adverse effects. In some patients, a low PLI may argue against viral pathogenicity and withholding acyclovir may be safe.
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Key messages
============

• With help of gallium-67-transferrin and technitiumggm-red blood cells, a pulmonary leak index can be measured as an index of capillary permeability and lung injury. In 7 patients with HSV-1 from tracheal aspirate or bronchoalveloar fluid, the index was normal, suggesting low pathogenicity of the virus.

• Low pulmonary pathogenicity of HSV-1 in the respiratory tracts argues for relatively harmless reactivation following immunodepression.

• When pulmonary pathogenicity is low, antiviral therapy may be safely withheld.
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Figures and Tables
==================

###### 

Clinical characteristics of study patients and ventilatory parameters at time of herpes simplex type 1 (HSV-1) isolation from tracheal aspirate (TA) or bronchoalveolar lavage (BAL).

  Patient                                                        1                                                  2                                       3                                                     4
  -------------------------------------------------------------- -------------------------------------------------- --------------------------------------- ----------------------------------------------------- ---------------------------------
  **General parameters:**                                                                                                                                                                                         
  Age                                                            45                                                 19                                      84                                                    78
  Gender                                                         ♀                                                  ♂                                       ♀                                                     ♂
  Underlying disease                                                                                                nasopharyngeal carcinoma                hypertension                                          heart failure
  Reason of admission                                            pneumonia of unknown origin; respiratory failure   septic shock; ALI/respiratory failure   aspiration pneumonia; respiratory failure and shock   Mycoplasma pneumoniae pneumonia
  Comorbidity                                                                                                       heart failure                           heart failure                                         prior coronary artery surgery
  Prior chemotherapy/radiotherapy                                                                                   \+                                                                                            
  Duration of mechanical ventilation prior to isolation, d       13                                                 5                                       10                                                    1
  Duration mechanical ventilation after isolation, d             8                                                  1                                       11                                                    6
  Length of stay ICU, d                                          26                                                 8                                       21                                                    42
  **Infectious parameters:**                                                                                                                                                                                      
  Duration between sampling and reporting positive cultures, d   5                                                  1                                       1                                                     1
  Respiratory source of HSV-1                                    BAL                                                TA                                      TA                                                    TA
  Other sources of HSV-1                                         throat, skin                                       throat                                                                                        
  Leukocytes in Gram stain of BAL/TA fluids                      few lymphocytes                                    few                                     moderate                                              few
  Bacteria in culture                                            S. aureus ++, C. albicans +                        C. albicans ++                          multiresistant P. aeruginosa, E. coli                 no micro-organisms
  Serology                                                       high titre IgG                                                                                                                                   
  Body temperature, °C                                           37.4                                               36.2                                    37.2                                                  38.2
  Blood leukocytes, × 10^9^/L                                    16.2                                               4.5                                     9.5                                                   16.4
  Antiviral therapy                                              acyclovir                                                                                  acyclovir                                             
  Treatment with steroids                                        prednison                                                                                                                                        
  **Respiratory parameters:**                                                                                                                                                                                     
  Arterial PO~2~/inspiratory FO~2~, mm Hg                        345                                                195                                     190                                                   98
  Plateau airway pressure, cm H~2~O                              33                                                 22                                      22                                                    20
  Positive end-expiratory airway pressure, cm H~2~O              12                                                 7                                       7                                                     5
  Total respiratory compliance, mL/cm H~2~O                      21                                                 31                                      31                                                    
  Radiographic score                                             4                                                  4                                       3                                                     4
  Lung injury score                                              2.5                                                2.5                                     2.2                                                   2.3
  Central venous pressure, mm Hg                                 10                                                 8                                                                                             
  Pulmonary leak index, × 10^-3^/min                             10.5                                               7.5                                     8.0                                                   14.0
  Duration between sampling and PLI, d                           0                                                  0                                       1                                                     2
